Description
METANO-XR 25 is an extended-release Metoprolol Succinate Tablet offered by Arrowin Pharmaceuticals, designed to provide a controlled effect on blood pressure and heart rate in a single daily dose. Being an extended-release cardioselective beta-1 blocker, METANO-XR 25 delivers the drug slowly for 24 hours, thus eliminating the fluctuations typical of immediate-release beta-blockers and ensuring more stable cardiovascular protection all day long. METANO-XR 25 is produced in compliance with WHO-GMP requirements and comes in handy blister strips of 15×10 pieces.
How It Works
Metoprolol Succinate selectively binds to the beta-1 adrenoreceptors found in abundance within the heart, resulting in diminished heart sensitivity to epinephrine and other catecholamines. The result is a decreased heart rate and cardiac contractility along with decreased cardiac output, thus lowering the pressure exerted by the heart and the work performed by it. The extended-release form results in gradual release of the drug in order to maintain constant blood concentration for the whole 24 hours.
Uses / Indications
- Essential (primary) hypertension
- Chronic stable angina pectoris
- Management of heart failure with reduced ejection fraction (as adjunct therapy, under specialist supervision)
- Reduction of cardiovascular risk in patients with coronary artery disease
- Rate control in certain cardiac arrhythmias, when directed by a physician
- Long-term maintenance therapy requiring smooth, once-daily heart-rate and blood-pressure control
Dosage & Administration
The standard METANO-XR 25 is administered at one tablet a day, preferably at the same time, whether the patient takes it with food or without, or as prescribed by the doctor. The tablet is to be swallowed whole with water, and the patient must not crush, break or chew the tablet because such actions will interfere with its extended release system and will release the entire dose instantly. Sudden stopping of the medication is never recommended since it may lead to a rebound effect in heart rate, blood pressure, or angina.
Side Effects
Most patients tolerate METANO-XR 25 well, though some may experience:
- Fatigue or tiredness
- Dizziness or light-headedness
- Slow heart rate (bradycardia)
- Cold hands and feet
- Headache
- Low blood pressure (hypotension)
- Gastrointestinal disturbances such as nausea or diarrhoea
- Sleep disturbances in some patients
Patients experiencing severe dizziness, fainting, an unusually slow pulse, or breathing difficulty should seek medical attention promptly.
Precautions & Warnings
- Only to be used on doctor’s advice
- Not to be prescribed to patients with severe bradycardia, significant heart block, or decompensated heart failure
- Cautious use should be made in patients having asthma, COPD, or other forms of bronchospastic respiratory diseases
- Cautious use should be made in patients with diabetes because of the masking effects of hypoglycemia by beta-blockers
- Cautious use should be made in patients with peripheral vascular disease
- Patients are not to be prescribed during pregnancy or lactation unless specifically advised by a physician
- Do not discontinue abruptly but rather taper off the dose gradually
- Regular monitoring of heart rate and blood pressure should be done during chronic treatment
Drug Interactions
METANO-XR 25 may interact with other antihypertensives, calcium channel blockers, antiarrhythmics, NSAIDs, and drugs that affect cardiac conduction or heart rate. Patients should always share a complete list of current medications with their doctor before beginning this therapy to avoid potentially serious interactions.
Storage
Store below 25°C in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.
PCD Pharma Franchise Opportunity for METANO-XR 25 — Arrowin Pharmaceuticals
Beta-blockers continue to be an important element in the treatment of patients suffering from high blood pressure and heart ailments in India, and their extended-release variants such as METANO-XR 25 have been favoured by doctors for their smoothness and better compliance of patients. METANO-XR 25, thus, stands to be a dependable, swift inclusion in the product line for franchise partners interested in cardiac diabetic products.
The product is manufactured through WHO-GMP, and its other features include fair pricing, comprehensive promotional material free of cost, and district-level monopoly rights in Arrowin’s monopoly model of India-wide monopoly system.
